Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12029MR)

This product GTTS-WQ12029MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12029MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9683MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ6782MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DS-8201
GTTS-WQ60MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ12593MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NVS250519
GTTS-WQ14021MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ14883MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ15226MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ6163MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CP-751871
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW